Holen Sie sich die Stockscreener-App
40.06
3.06%
1.19
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$38.87
Offen:
$39.02
24-Stunden-Volumen:
894.03K
Relative Volume:
0.43
Marktkapitalisierung:
$6.13B
Einnahmen:
$616.29M
Nettoeinkommen (Verlust:
$447.18M
KGV:
14.43
EPS:
2.7771
Netto-Cashflow:
$-24.99M
1W Leistung:
+1.60%
1M Leistung:
+9.39%
6M Leistung:
+19.90%
1J Leistung:
+15.88%
1-Tages-Spanne:
$38.73
$40.10
1-Wochen-Bereich:
$38.53
$40.64
52-Wochen-Spanne:
$25.28
$44.65
Tg Therapeutics Inc Stock (TGTX) Company Profile
Firmenname
Tg Therapeutics Inc
Sektor
Branche
Telefon
(212) 554-4484
Adresse
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
40.07 | 5.95B | 616.29M | 447.18M | -24.99M | 2.7771 |
VRTX
Vertex Pharmaceuticals Inc
|
436.71 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.47 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.47 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.95 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.71 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2024-10-29 | Eingeleitet | TD Cowen | Buy |
| 2023-08-02 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-26 | Fortgesetzt | Jefferies | Buy |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2018-09-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-04-25 | Eingeleitet | Jefferies | Buy |
| 2017-03-06 | Bestätigt | FBR & Co. | Outperform |
| 2016-10-06 | Fortgesetzt | Brean Capital | Buy |
| 2016-05-27 | Eingeleitet | SunTrust | Buy |
| 2015-12-01 | Eingeleitet | FBR Capital | Outperform |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-19 | Bestätigt | Brean Capital | Buy |
| 2014-12-11 | Bestätigt | ROTH Capital | Buy |
| 2014-12-10 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
TGTX stock rises 29% in 3 months: Here's what you should know - MSN
TG Therapeutics to Present New Data on BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting - Quiver Quantitative
TG Therapeutics Announces Data Presentations for BRIUMVI® - GlobeNewswire
TG Therapeutics, Inc. (TGTX) Stock Analysis: Exploring a 23% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
TGTX Q1 earnings miss, sales rise Y/Y, stock up on raised 2026 view - MSN
How Investors May Respond To TG Therapeutics (TGTX) Boosting 2026 Guidance On Stronger Briumvi Sales - Sahm
TGTX Technical Analysis | Trend, Signals & Chart Patterns | TG THERAPEUTICS INC (NASDAQ:TGTX) - ChartMill
TGTX stock hits fresh 52-week high – here’s why retail is bullish despite Q1 earnings miss - MSN
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know - sharewise.com
Earnings call transcript: TG Therapeutics Q1 2026 misses EPS expectations By Investing.com - Investing.com Nigeria
TG Therapeutics, Inc. (TGTX) Stock Analysis: Potential 21.52% Upside Sparks Investor Interest - DirectorsTalk Interviews
TG Therapeutics, Inc.Common Stock (NQ: TGTX - The Chronicle-Journal
Technical Reactions to TGTX Trends in Macro Strategies - Stock Traders Daily
TGTX Stock Price, Quote & Chart | TG THERAPEUTICS INC (NASDAQ:TGTX) - ChartMill
TG Therapeutics Stock Story Gains Interest In Nasdaq Index - Kalkine Media
TG Therapeutics' (NASDAQ:TGTX) Earnings Aren't As Good As They Appear - Yahoo Finance
Earnings call transcript: TG Therapeutics Q1 2026 misses EPS, stock surges - Investing.com UK
TG Therapeutics outlines $925M 2026 global revenue guidance while targeting ~$220M Q2 US BRIUMVI net revenue - MSN
Earnings call transcript: TG Therapeutics Q1 2026 misses EPS, stock surges By Investing.com - Investing.com Australia
Signal Says Which Biotech to Buy This Week - Schaeffer's Investment Research
A Look At TG Therapeutics (TGTX) Valuation After Record Q1 Revenue And Higher 2026 Guidance - Sahm
Why TG Therapeutics (TGTX) Is Up 27.4% After Raising 2026 Revenue Guidance On BRIUMVI Strength - Yahoo Finance
Assessing TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum - Yahoo Finance
TG THERAPEUTICS INC (NASDAQ:TGTX) Screens as Affordable Growth Play with Strong Revenue Surge and Discounted Valuation - ChartMill
MSN Money - MSN
TG Therapeutics (TGTX) Q1 2026 Results Put 66% Net Margin Narrative To The Test - Sahm
TG Therapeutics (TGTX) Q1 2026 Earnings Transcript - AOL.com
TGTX Stock Quote Price and Forecast - CNN
TGTX Reports Strong Q1 Revenue Growth and Upgraded Guidance - GuruFocus
Number of shareholders of TG Therapeutics, Inc. – LSX:A1JXW7 - TradingView
TG Therapeutics Stock 6-Day Winning Spree: Stock Climbs 28% - Trefis
6-Day Rally Sends TG Therapeutics Stock Up 28% - Trefis
TG Therapeutics Earnings Call Highlights Explosive Growth - The Globe and Mail
Finanzdaten der Tg Therapeutics Inc-Aktie (TGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):